Patrick John Finn Sells 476 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 476 shares of Twist Bioscience stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $48.00, for a total value of $22,848.00. Following the sale, the chief operating officer now directly owns 173,419 shares of the company’s stock, valued at approximately $8,324,112. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Friday, May 3rd, Patrick John Finn sold 2,311 shares of Twist Bioscience stock. The stock was sold at an average price of $37.13, for a total value of $85,807.43.
• On Tuesday, April 23rd, Patrick John Finn sold 2,174 shares of Twist Bioscience stock. The stock was sold at an average price of $30.12, for a total transaction of $65,480.88.

Twist Bioscience Trading Up 0.9 %

Shares of TWST stock traded up $0.45 during mid-day trading on Friday, reaching $48.45. The stock had a trading volume of 258,253 shares, compared to its average volume of 1,038,783. The stock’s 50-day moving average price is $45.23 and its two-hundred day moving average price is $38.71. Twist Bioscience Co. has a 52-week low of $14.42 and a 52-week high of $55.26. The firm has a market capitalization of $2.82 billion, a PE ratio of -14.42 and a beta of 1.80.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The firm had revenue of $75.30 million for the quarter, compared to analysts’ expectations of $70.70 million. During the same quarter in the previous year, the company earned ($1.06) earnings per share. The company’s revenue for the quarter was up 25.1% compared to the same quarter last year. On average, equities research analysts forecast that Twist Bioscience Co. will post -3.08 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience in the 4th quarter worth about $30,000. Federated Hermes Inc. bought a new stake in Twist Bioscience during the third quarter worth about $29,000. Headlands Technologies LLC purchased a new stake in Twist Bioscience in the first quarter worth about $124,000. GAMMA Investing LLC increased its stake in shares of Twist Bioscience by 1,896.8% during the second quarter. GAMMA Investing LLC now owns 3,754 shares of the company’s stock valued at $185,000 after purchasing an additional 3,566 shares in the last quarter. Finally, International Assets Investment Management LLC lifted its holdings in shares of Twist Bioscience by 3,519.8% during the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock valued at $148,000 after purchasing an additional 3,907 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on TWST shares. Robert W. Baird increased their target price on shares of Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Scotiabank lifted their price objective on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a report on Monday, May 6th. Guggenheim started coverage on Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 target price for the company. Barclays increased their price objective on Twist Bioscience from $45.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, June 28th. Finally, Evercore ISI lifted their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $48.50.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.